Publications

Chapters, Manuals and Guidelines

• Pink Book's Chapter on Meningococcal Disease
  Epidemiology & Prevention of Vaccine-Preventable Diseases
• Travelers' Health: Yellow Book - Chapter on Meningococcal Disease
  CDC's Health Information for International Travel (Prevention of Specific Infectious Diseases)
• Surveillance Manual's Chapter on Meningococcal Disease
  Manual for the Surveillance of Vaccine-Preventable Diseases

Vaccine Recommendations and Licensures

• Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2013;62(RR02):1-22.
• Infant Meningococcal Vaccination: Advisory Committee on Immunization Practices (ACIP) Recommendations and Rationale. MMWR. 2013;62(03):52-4.
• Recommendations of the Advisory Committee on Immunization Practices (ACIP) for Use of Quadrivalent Meningococcal Conjugate Vaccine (MenACWY-D) Among Children Aged 9 Through 23 Months at Increased Risk for Invasive Meningococcal Disease. MMWR. 2011;60(40):1391-2.
• Licensure of a Meningococcal Conjugate Vaccine for Children Aged 2 Through 10 Years and Updated Booster Dose Guidance for Adolescents and Other Persons at Increased Risk for Meningococcal Disease - Advisory Committee on Immunization Practices (ACIP), 2011. MMWR. 2011;60(30):1018-9.
• Updated Recommendations for Use of Meningococcal Conjugate Vaccines - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR. 2011;60(03):72-6.
• Licensure of a Meningococcal Conjugate Vaccine (Menveo) and Guidance for Use - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR. 2010;59(09):273.
• Updated Recommendation from the Advisory Committee on Immunization Practices (ACIP) for Revaccination of Persons at Prolonged Increased Risk for Meningococcal Disease. MMWR. 2009;58(37):1042-43.
• Report from the Advisory Committee on Immunization Practices (ACIP): Decision Not to Recommend Routine Vaccination of All Children Aged 2-10 Years with Quadrivalent Meningococcal Conjugate Vaccine (MCV4). MMWR. 2008;57(17):462-465.
• Revised Recommendations of the Advisory Committee on Immunization Practices to Vaccinate All Persons Aged 11--18 Years with Meningococcal Conjugate Vaccine. MMWR. 2007;56(31)794-5.
• Prevention and Control of Meningococcal Disease (ACIP Recommendations). MMWR. 2005;54(RR-7).
• Meningococcal Disease and College Students: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2000; 49 (RR-7): 11-20.
• Change in Recommendation for Meningococcal Vaccine for Travelers . MMWR. 1999;48(05):104.

Top of Page

Surveillance, Epidemiology and Outbreaks

• Mandal S, Wu HM, MacNeil JR, Machesky K, Garcia J, Plikaytis BD, Quinn K, King L, Schmink SE, Wang X, Mayer LW, Clark TA, Gaskell JR, Messonnier NE, DiOrio M, Cohn AC. Prolonged university outbreak of meningococcal disease associated with a serogroup B strain rarely seen in the United States. Clin Infect Dis. 2013;57:344-8.
• Kristiansen PA, Diomandé F, Ba AK, Sanou I, Ouédraogo AS, Ouédraogo R, Sangaré L, Kandolo D, Aké F, Saga IM, Clark TA, Misegades L, Martin SW, Thomas JD, Tiendrebeogo SR, Hassan-King M, Djingarey MH, Messonnier NE, Préziosi MP, Laforce FM, Caugant DA. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis. 2013;56:354-63.
• Cohn AC, Harrison LH. Meningococcal vaccines: current issues and future strategies. Drugs. 2013;73:1147-55.
• Terranella A, Beekmann SE, Polgreen PM, Cohn A, Wu HM, Clark TA. Practice patterns of infectious disease physicians for management of meningococcal disease. Pediatr Infect Dis J. 2012;31:e208–12.
• Djingarey MH, Barry R, Bonkoungou M, Tiendrebeogo S, Sebgo R, Kandolo D, Lingani C, Preziosi MP, Zuber PL, Perea W, Hugonnet S, Dellepiane de Rey Tolve N, Tevi-Benissan C, Clark TA, Mayer LW, Novak R, Messonier NE, Berlier M, Toboe D, Nshimirimana D, Mihigo R, Aguado T, Diomandé F, Kristiansen PA, Caugant DA, Laforce FM. Effectively introducing a new meningococcal A conjugate vaccine in Africa: The Burkina Faso experience. Vaccine. 2012;30 Suppl 2:B40–5.
• Cohn AC, Messonnier NE. Inching toward a serogroup B meningococcal vaccine for infants. JAMA. 2012;307:614–5.
• Terranella A, Cohn A, Clark T. Meningococcal conjugate vaccines: optimizing global impact. Infect Drug Resist. 2011;4:161-9.
• MacNeil JR, Thomas JD, Cohn AC. Meningococcal disease: shifting epidemiology and genetic mechanisms that may contribute to serogroup C virulence. Curr Infect Dis Rep. 2011;13:374-9.
• MacNeil JR, Cohn AC, Zell ER, Schmink S, Miller E, Clark T, Messonnier NE, Active Bacterial Core surveillance (ABCs) Team and MeningNet Surveillance Partners. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Pediatr Infect Dis J. 2011;30:451-5.
• Thigpen MC, Whitney CG, Messonnier NE, Zell ER, Lynfield R, Hadler JL, et al. Emerging Infections Programs Network. Bacterial meningitis in the United States, 1998-2007. N Engl J Med. 2011;364:2016-25.
• Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50:184-91.
• Cohen C, Singh E, Wu HM, Martin S, de Gouveia L, Klugman KP, von Gottberg A; Group for Enteric, Respiratory and Meningeal disease Surveillance in South Africa (GERMS-SA), et al. Increased incidence of meningococcal disease in HIV-infected individuals associated with higher case-fatality ratios in South Africa.. AIDS. 2010;24(9):1351-60.
• Wu HM, Harcourt BH, Hatcher CP, Wei SC, Novak RT, Wang X, et al. Emergence of Ciprofloxacin-Resistant Neisseria meningitidis in North America. N Engl J Med. 2009;360:886-92.
• Weiss D, Stern EJ, Zimmerman C, Bregman B, Yeung A, Das D, Dentinger CM, Marx MA, Kornblum J, Lee L, Halse TA, Mayer LW, Hatcher CP, Theodore MJ, Schmink S, Harcourt BH, Zucker JR, Layton M, Clark TA. Epidemiologic investigation and targeted vaccination initiative in response to an outbreak of meningococcal disease among illicit drug users in Brooklyn, New York. Clin Infect Dis. 2009;48:894-901.
• CDC. Emergence of -resistant Neisseria meningitidis-Minnesota and North Dakota, 2007-2008. MMWR. 2008;57(07):173-175.
• Dull P, Abdelwahab J, Sacchi C, Becker M, Noble C, Kaiser R, et al. Neisseria meningitidis Serogroup W-135 Carriage among US Travelers to the 2001 Hajj. J Infect Dis. 2005;191:33-9.
• Rainbow J, Cebelinski E, Bartkus J, Glennen A, Boxrud D, Lynfield R. Rifampin-resistant Meningococcal Disease. Emerg Infect Dis. 2005;11(6):977-9.
• Shepard CW, Ortega-Sanchez IR, Scott RD, Rosenstein NE, ABCs Team. Cost-Effectiveness of Conjugate Meningococcal Vaccination Strategies in the United States. Pediatrics. 2005;115(5):1220-32.
• McEllistrem MC, Kolano JA, Pass MA, Caugant DA, Mendelsohn A, Pacheco AGF, et al. Correlating Epidemiologic Trends with the Genotypes Causing Meningococcal Disease, Maryland. Emerg Infect Dis. 2004;10(3):451-6.
• Shepard CW, Rosenstein NE, Fischer M, and the Active Bacterial Core Surveillance Team. Neonatal meningococcal disease in the United States, 1990-1999. Pediatr Infect Dis J. 2003;22:418-22.
• Kellerman S, McCombs K, Ray M, Farley MM, Rosenstein N, Popovic T, Blake P, Stephens DS, and the Georgia Emerging Infections Program. Genotype-Specific Carriage of Neisseria meningitidis in Georgia Counties with Hyper- and Hyposporadic Rates of Meningococcal Disease. J Infect Dis. 2002;186:40-8.
• Rosenstein N, Perkins B, Stephens D, Popovic T, Hughes J. Meningococcal Disease. NEJM. 2001; 344:1378-1388.
• Sacchi C, Whitney A, Popovic T, et al. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998. J Infect Dis. 2000; 182:1169-1176.
• Serogroup W-135 Meningococcal Disease Among Travelers Returning From Saudi Arabia - United States, 2000. MMWR. 2000;49(16):345-6.
• CDC. Meningococcal Disease – New England, 1993 - 1998. MMWR. 1999;48(29):629-633.
• Campagne G, Schuchat A, Djibo S, Ousseini A, Cisse L, Chippaux J. Epidemiology of bacterial meningococcal in Niamey, Niger, 1981-1996. Bull World Health Organ. 1999; 77: 499-508.
• CDC. Control and Prevention of Meningococcal Disease and Control and Prevention of Serogroup C Meningococcal Disease: Evaluation and Management of Suspected Outbreaks. MMWR. 1997;46(RR-5):1-51.
• CDC. Serogroup Y Meningococcal Disease – Illinois, Connecticut, and Selected Areas, United States, 1989-1996. MMWR. 1996;45(46):1010-4.
• Serogroup B Meningococcal Disease - Oregon, 1994. MMWR. 1995;44(07):121-124.
• CDC. Lab-Based Surveillance for Meningococcal Disease - U.S., 1989-91. MMWR. 1993;42(SS-2):21-30.

Laboratory

• Wu HM, Cordeiro SM, Harcourt BH, Carvalho M, Azevedo J, Oliveira TQ, Leite MC, Salgado K, Reis MG, Plikaytis BD, Clark TA, Mayer LW, Ko AI, Martin SW, Reis JN. Accuracy of real-time PCR, Gram stain and culture for Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae meningitis diagnosis. BMC Infect Dis. 2013;22:13:26.
• Rishishwar L, Katz LS, Sharma NV, Rowe L, Frace M, Dolan Thomas J, Harcourt BH, Mayer LW, Jordan IK. Genomic basis of a polyagglutinating isolate of Neisseria meningitidis. J Bacteriol. 2012;194:5649–56.
• Thomas J, Hatcher CP, Satterfield DA, Theodore MJ, Bach MC, Linscott KB, Zhao X, Wang X, Mair R, Schmink S, Arnold KE, Stephens DS, Harrison LH, Hollick RA, Andrade AL, Lamaro-Cardoso J, de Lemos AP, Gritzfeld J, Gordon S, Soysal A, Bakir M, Sharma D, Jain S, Satola SW, Messonnier NE, Mayer LW. sodC-based real-time PCR for detection of Neisseria meningitidis. PLoS One. 2011;6:e19361.
• Dolan Thomas J, Hatcher CP, Satterfield DA, Theodore MJ, Bach MC, Linscott KB, et al. sodC-based real-time PCR for detection of Neisseria meningitidis. PLoS One. 2011;6:e19361.
• Harris SL, Zhu D, Murphy E, McNeil LK, Wang X, Mayer LW, et al. Preclinical evidence for the potential of a vivalent fHBP vaccine to prevent Neisseria meningitidis serogroup C disease. Hum Vaccin. 2011;7:68-74.
• Katz LS, Humphrey JC, Conley AB, Nelakuditi V, Kislyuk AO, Agrawal S, et al. Neisseria Base: a comparative genomics database for Neisseria meningitidis. Database. Epub ahead of print. Sept 2011.
• Marsh JW, Shutt KA, Pajon R, Tulenko MM, Liu S, Hollick RA, et al. Diversity of factor H-binding protein in Neisseria meningitidis carriage isolates. Vaccine. 2011;29:6049-58.
• Wang X, Cohn A, Comanducci M, Andrew L, Zhao X, Macneil JR, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine. 2011;29:4739-44.
• Harrison, LH, Shutt, KA, Schmink, S, Marsh, JW, Harcourt, BH, Wang, X, et al. Population structure of Invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era, United States, 2000-2005. J Infect Dis. 2010;201:1208-24.
• Kislyuk, AO, Katz, LS, Agrawal, S, Hagen, MS, Conley, AB, Jayaraman, P, et al. A computational genomics pipeline for microbial sequencing projects. Bioinformatics. 2010;26:1819-26.
• Katz LS, Bolen CR, Harcourt BH, Schmink S, Wang X, Kislyuk A, et al. Meningococcus genome informatics platform: a system for analyzing multilocus sequence typing data. Nucleic Acids Res, 2009;37:606-11.
• Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, Fink PS, et al. Sequence diversity of the Factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis. 2009;200:379-89.
• Whitney AM, Coulson GB, von Gottberg A, Block C, Keller N, Mayer LW, et al. Genotypic comparison of invasive Neisseria meningitidis serogroup Y isolates from the United States, South Africa, and Israel, isolated from 1999 through 2002. J Clin Microbiol. 2009;47:2787-93.
• Borrow R, Carlone GM, Rosenstein N, Blake M, Feavers I, Martin D, et al. and The Meningococcal Working Group. Neisseria meningitidis group B correlates of protection and assay standardization – International Meeting Report, Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine. 2006;24:5093-107.
• Sejvar JJ, Johnson D, Popovic T, Miller JM, Downes F, Somsel P, et al. Assessing the risk of laboratory-acquired meningococcal disease in the United States, 1996-2000. J Clin Microbiol. 2005;24:4811-4.
• Mothershed EA, Sacchi CT, Whitney AM, et al. Use of Real-Time PCR To Resolve Slide Agglutination Discrepancies in Serogroup Identification of Neisseria meningitidis. J Clin Microbiol. 2004;42(1):320-28.

Top of Page